Dexcom earnings were $680.8M for the trailing 12 months ending Sep 30, 2024, with 77.6% growth year over year. The latest DXCM earnings report on Sep 30, 2024 announced Q3 2024 earnings of $134.6M, down 6.2% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, DXCM reported annual earnings of $541.5M, with 58.7% growth.
DXCM past earnings growth
How has DXCM's earnings growth performed historically?
On DXCM's earnings call on Invalid Date, Dexcom (NASDAQ: DXCM) reported Q3 2024 earnings per share (EPS) of $0.34, up 9.68% year over year. Total DXCM earnings for the quarter were $134.60 million. In the same quarter last year, Dexcom's earnings per share (EPS) was $0.31.
As of the last Dexcom earnings report, Dexcom is currently profitable. Dexcom's net profit (also called net income) for the twelve months ending Sep 30, 2024 was $680.80 million, a 80.58% increase year over year.
What was DXCM's earnings growth in the past year?
As of Dexcom's earnings date in Invalid Date, Dexcom's earnings has grown 77.55% year over year. This is 38.99 percentage points higher than the US Medical Devices industry earnings growth rate of 38.56%. DXCM earnings in the past year totalled $680.80 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.